Approval · Notice of Compliance 16275 · 2014
PMS-ELETRIPTAN: Notice of Compliance 16275
Issued November 12, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16275
- Date
- November 12, 2014
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- 5-ht1 receptor agonist; migraine therapy
- Canadian reference product
- RELPAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PMS-ELETRIPTAN | 02434342 | Dormant |
| PMS-ELETRIPTAN | 02434350 | Dormant |
Medicinal ingredients
- ELETRIPTAN HYDROBROMIDE 20 MG per TAB
- ELETRIPTAN HYDROBROMIDE 40 MG per TAB